Targeting epigenetic changes in North American adult T‑cell leukemia/lymphoma
Epigenetic Alterations and Targeted Therapies in North American ATLL
['FUNDING_R01'] · ALBERT EINSTEIN COLLEGE OF MEDICINE · NIH-11309665
Looking at whether drugs that reverse epigenetic changes or block BCL6 can help people in North America with adult T‑cell leukemia/lymphoma (ATLL).
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | ALBERT EINSTEIN COLLEGE OF MEDICINE (nih funded) |
| Locations | 1 site (BRONX, UNITED STATES) |
| Trial ID | NIH-11309665 on ClinicalTrials.gov |
What this research studies
Researchers will analyze tumor samples from North American people with ATLL to find epigenetic changes such as mutations in EP300 and to measure BCL6 activity. They will test drugs that alter DNA methylation and compounds that inhibit BCL6 in ATLL cell lines and laboratory models. The team will compare findings from North American ATLL to Japanese ATLL to explain differences in treatment response and outcomes. Results are intended to point toward new targeted treatment options and inform future clinical trials for patients with chemo‑resistant disease.
Who could benefit from this research
Good fit: People diagnosed with the North American variant of ATLL, particularly those with chemo‑refractory disease or tumors showing epigenetic changes like EP300 mutations or high BCL6 activity.
Not a fit: Patients whose disease is not ATLL, or whose tumors lack the specific epigenetic alterations studied, may not benefit from the approaches in this project.
Why it matters
Potential benefit: Could identify targeted therapies that improve outcomes for people with North American ATLL, especially those who do not respond to standard chemotherapy.
How similar studies have performed: Laboratory studies in other cancers support epigenetic drugs and BCL6 targeting as promising approaches, but applying these strategies to North American ATLL is relatively new.
Where this research is happening
BRONX, UNITED STATES
- ALBERT EINSTEIN COLLEGE OF MEDICINE — BRONX, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: YE, BIHUI HILDA — ALBERT EINSTEIN COLLEGE OF MEDICINE
- Study coordinator: YE, BIHUI HILDA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.